Welcome to our dedicated page for Nuvasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on Nuvasive stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvasive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvasive's position in the market.
NuVasive, Inc. (NASDAQ: NUVA) announced that CEO Chris Barry will present virtually at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 8:10 a.m. PT. The presentation aims to highlight the company's innovative spine technology solutions designed for minimally disruptive surgeries. A live webcast will be available on the company's Investor Relations page, with a replay accessible for 30 days post-event. NuVasive, a leader in spine technology, reported over $1 billion in net sales and operates in more than 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) will release its fourth quarter and full year 2021 results on February 23, 2022, after market close. The company will also hold a conference call at 4:30 p.m. ET to discuss financial performance, including net sales exceeding $1 billion. A live webcast and archived replay will be available on their website. The release and call may include forward-looking statements regarding net sales and profitability, which are subject to risks and uncertainties.
NuVasive, Inc. (NASDAQ: NUVA) appointed Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO), effective February 7, 2022. Morton brings over 25 years of HR experience, previously serving at Wright Medical and Hanger. His expertise in talent development and employee experience is expected to support NuVasive's growth and cultural transformation. CEO Chris Barry emphasized Morton's alignment with the company's core values, enhancing the leadership team during a pivotal growth phase.
NuVasive (NASDAQ: NUVA) announced FDA 510(k) clearance for expanded indications of use for Attrax® Putty, marking it as the first synthetic biologic approved for thoracolumbar spine interbody fusions. This innovative bone void filler exhibits osteoconductive properties and competes favorably with autograft bone in clinical studies. The clearance enables its use with NuVasive's Advanced Materials Science portfolio, enhancing spine surgery solutions. The company's commitment to advancing spine care aims to deliver both clinical efficacy and economic value.
NuVasive, a leader in spine technology, announced that CEO Chris Barry will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 12:00 p.m. PT. The presentation will focus on minimally invasive surgical solutions and innovations in spine technology. A live webcast will be accessible on the Company's Investor Relations page, with a replay available for 30 days. With over $1 billion in net sales and a presence in more than 50 countries, NuVasive is committed to advancing surgical care and improving patient outcomes.
NuVasive, a leader in spine technology, announced that CEO J. Christopher Barry will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The pre-recorded chat will be available for on-demand viewing starting November 23, 2021, at 9:00 a.m. PT. The webcast and archived recording can be accessed on NuVasive's Investor Relations page. With over $1 billion in net sales and approximately 2,700 employees worldwide, NuVasive focuses on transformative spine surgery solutions and serves a diverse global clientele.
NuVasive (NASDAQ: NUVA) reported a third quarter 2021 net sales decline of 8.3%, totaling $270.8 million, down from $295.3 million year-over-year. GAAP diluted loss per share was $0.42, compared to a profit of $0.11 in the prior year. The company attributed challenges to the COVID-19 pandemic and staffing shortages. Full-year guidance was lowered, projecting net sales between $1.132 billion and $1.142 billion, down from $1.190 billion to $1.210 billion. However, NuVasive extended its share repurchase program and increased authorization to $100 million.
NuVasive, a leader in spine technology, will present virtually at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021, at 8:20 a.m. PT. The presentation will be accessible via a live webcast on their website. A replay will be available for 30 days post-event. With over $1 billion in net sales and operations in 50 countries, NuVasive focuses on less-invasive surgical solutions, aiming to transform surgery and improve patient outcomes.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, will sponsor and participate in the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum 2021 in Las Vegas from October 28 to 30, 2021. The company aims to support research and education on less invasive spine surgery, highlighting its benefits such as reduced operating room time and lower risks. NuVasive will showcase its virtual reality training module for its X360® system and host various events recognizing contributions to minimally invasive surgery.
NuVasive, Inc. (NASDAQ: NUVA) has announced a new virtual reality (VR) training module for the NuVasive X360® system, designed to enhance their Clinical Professional Development (CPD) program. Developed in collaboration with PrecisionOS®, this module provides surgeons and sales representatives with a hands-on learning experience in spine surgery, available in 20 languages. PrecisionOS technology has shown to significantly accelerate learning and improve surgical skills, potentially leading to better patient outcomes. The module will be showcased at an upcoming forum in Las Vegas from October 28-30, 2021.